DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April 27, 2023 , the Compensation Committee of Precision’s...